Where does Newsoara play into this? My understanding is that Zenith/Newsoara were already collaborating together for Phase 2b development of ZEN-3694 w/ enzalutamide for mCRPC? Is today's Astella's announcment a different Phase 2b trial? Is this China/Newsoara trial running in parallel? Is Astella's trial running in place of the China/Newsoara trial?

https://www.zenithepigenetics.com/programs/business-strategy

"Newsoara BioPharm Co., Ltd. (Newsoara) - China Regional Partnership

In 2019, Zenith entered into a licensing agreement with Newsoara to develop ZEN-3694 for the China, Hong Kong, Taiwan and Macau markets. Newsoara owns 100% of the development and commercialization rights for ZEN-3694 in these markets and is responsible for all associated costs. In exchange for these rights, Zenith received an upfront payment and is eligible for development and commercial milestone payments and royalties. Zenith and Newsoara are currently collaborating to develop ZEN-3694 + enzalutamide in combination to treat metastatic castration resistant prostate cancer (mCRPC) in a planned China/USA Phase 2b randomized trial."